GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fuan Pharmaceutical (Group) Co Ltd (SZSE:300194) » Definitions » Piotroski F-Score

Fuan Pharmaceutical (Group) Co (SZSE:300194) Piotroski F-Score : 4 (As of Apr. 25, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Fuan Pharmaceutical (Group) Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Fuan Pharmaceutical (Group) Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Fuan Pharmaceutical (Group) Co's Piotroski F-Score or its related term are showing as below:

SZSE:300194' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 9
Current: 4

During the past 13 years, the highest Piotroski F-Score of Fuan Pharmaceutical (Group) Co was 9. The lowest was 2. And the median was 6.


Fuan Pharmaceutical (Group) Co Piotroski F-Score Historical Data

The historical data trend for Fuan Pharmaceutical (Group) Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fuan Pharmaceutical (Group) Co Piotroski F-Score Chart

Fuan Pharmaceutical (Group) Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 2.00 6.00 6.00 6.00

Fuan Pharmaceutical (Group) Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 4.00 5.00 6.00 4.00

Competitive Comparison of Fuan Pharmaceutical (Group) Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Fuan Pharmaceutical (Group) Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fuan Pharmaceutical (Group) Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fuan Pharmaceutical (Group) Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Fuan Pharmaceutical (Group) Co's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was 93.977 + 85.129 + -21.77 + 69.049 = ¥226 Mil.
Cash Flow from Operations was 92.773 + 53.498 + 2.742 + 26.709 = ¥176 Mil.
Revenue was 623.613 + 562.27 + 396.186 + 467.678 = ¥2,050 Mil.
Gross Profit was 351.733 + 292.027 + 209.686 + 190.526 = ¥1,044 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was
(6018.781 + 5997.291 + 6040.326 + 5978.583 + 6079.333) / 5 = ¥6022.8628 Mil.
Total Assets at the begining of this year (Mar24) was ¥6,019 Mil.
Long-Term Debt & Capital Lease Obligation was ¥400 Mil.
Total Current Assets was ¥2,162 Mil.
Total Current Liabilities was ¥1,076 Mil.
Net Income was 74.865 + 90.953 + -19.972 + 122.5 = ¥268 Mil.

Revenue was 637.495 + 654.466 + 664.766 + 809.4 = ¥2,766 Mil.
Gross Profit was 351.494 + 350.826 + 308.573 + 413.025 = ¥1,424 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was
(6295.381 + 6300.515 + 6165.437 + 5975.931 + 6018.781) / 5 = ¥6151.209 Mil.
Total Assets at the begining of last year (Mar23) was ¥6,295 Mil.
Long-Term Debt & Capital Lease Obligation was ¥384 Mil.
Total Current Assets was ¥2,148 Mil.
Total Current Liabilities was ¥1,215 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Fuan Pharmaceutical (Group) Co's current Net Income (TTM) was 226. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Fuan Pharmaceutical (Group) Co's current Cash Flow from Operations (TTM) was 176. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=226.385/6018.781
=0.0376131

ROA (Last Year)=Net Income/Total Assets (Mar23)
=268.346/6295.381
=0.04262586

Fuan Pharmaceutical (Group) Co's return on assets of this year was 0.0376131. Fuan Pharmaceutical (Group) Co's return on assets of last year was 0.04262586. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Fuan Pharmaceutical (Group) Co's current Net Income (TTM) was 226. Fuan Pharmaceutical (Group) Co's current Cash Flow from Operations (TTM) was 176. ==> 176 <= 226 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=399.659/6022.8628
=0.06635698

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=383.589/6151.209
=0.06235994

Fuan Pharmaceutical (Group) Co's gearing of this year was 0.06635698. Fuan Pharmaceutical (Group) Co's gearing of last year was 0.06235994. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=2162.385/1075.544
=2.01050352

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=2148.46/1215.022
=1.76824782

Fuan Pharmaceutical (Group) Co's current ratio of this year was 2.01050352. Fuan Pharmaceutical (Group) Co's current ratio of last year was 1.76824782. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Fuan Pharmaceutical (Group) Co's number of shares in issue this year was 1150.817. Fuan Pharmaceutical (Group) Co's number of shares in issue last year was 1225.001. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1043.972/2049.747
=0.50931749

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1423.918/2766.127
=0.51476957

Fuan Pharmaceutical (Group) Co's gross margin of this year was 0.50931749. Fuan Pharmaceutical (Group) Co's gross margin of last year was 0.51476957. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=2049.747/6018.781
=0.3405585

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=2766.127/6295.381
=0.43938993

Fuan Pharmaceutical (Group) Co's asset turnover of this year was 0.3405585. Fuan Pharmaceutical (Group) Co's asset turnover of last year was 0.43938993. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+0+1+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Fuan Pharmaceutical (Group) Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Fuan Pharmaceutical (Group) Co  (SZSE:300194) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Fuan Pharmaceutical (Group) Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Fuan Pharmaceutical (Group) Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fuan Pharmaceutical (Group) Co Business Description

Traded in Other Exchanges
N/A
Address
No.1 Huanan 1 Road, Changshou District, Chongqing, CHN, 401254
Fuan Pharmaceutical (Group) Co Ltd is mainly engaged in the production and sales of bulk drugs and preparations. The company mainly deals with anti-infective, anti-tumor, mental nervous system, cardiovascular and cerebrovascular, digestive system, endocrine and metabolic, bone and muscle systems. Its products include penicillin and cephalosporins.
Executives
Wu Xiong Hui Executives
Huang Tao Directors, executives
Feng Jing Executives
Yu Xue Song Directors, executives
Hong Rong Chuan Executives
Tang Qin Secretary, Director
Wang Tian Xiang Director
Sun Yong Ping Executives
Jiang Chen Directors, executives
Huang Dao Fei Supervisors
Wen Min Director
Zhou Xu Dong Executives
Zhou Zhong Sheng Supervisors

Fuan Pharmaceutical (Group) Co Headlines

No Headlines